Collagenase Clostridium histolyticum in the treatment of Peyronie's disease: patient selection and perspectives.
Ontology highlight
ABSTRACT: The safety and efficacy of the use of collagenase Clostridium histolyticum (CCH) for the treatment of Peyronie's disease has been confirmed over the past several years. However, identification of the ideal patient population for use of this treatment is not well established. Multiple studies have attempted to delineate various patient-specific factors that may predict response to treatment with CCH, with the intent of enhancing patient selection. To date, these include baseline curvature severity, duration of disease, disease phase at presentation, plaque calcification, baseline erectile function, plaque size, age, comorbid diabetes, previous penile trauma, responsiveness to first treatment cycle, baseline penile shortening or pain, prior treatment with intralesional injection, comp
SUBMITTER: Kuhlmann PK
PROVIDER: S-EPMC5338950 | biostudies-literature | 2017
REPOSITORIES: biostudies-literature
ACCESS DATA